CORBUS PHARMACEUTICALS HOLDINGS

Founded in 2009, Corbus is a clinical-stage pharmaceutical company advancing new treatments for cancer and obesity, two of the most urgent health challenges of our time... At Corbus, we are experienced scientists, clinicians, and industry leaders, united by a shared vision: to advance and deliver therapies that have the potential to change lives. With deep roots in medical research and a strong sense of purpose, we've built a team grounded in both expertise and integrity... Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus' pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells, and..

Also known as: Corbus, Corbus Pharmaceuticals Holdings, Inc.

Primary location: Norwood United States